ZDA
AGIO icon

Zweig-DiMenna Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Zweig-DiMenna Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-46,483
Closed -$2.85M – 265
2014
Q3 		$2.85M Buy
+46,483
New +$2M 0.12% 127

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Zweig-DiMenna Associates's AGIO Position: Q4 2014 in Review

Zweig-DiMenna Associates sold out of Agios Pharmaceuticals (AGIO) in Q4 2014, closing a stake of 46,483 shares — an estimated $2.85M sold.

Zweig-DiMenna Associates first reported a position in AGIO in Q3 2014 and held it in 1 quarter. The position peaked at $2.85M in Q3 2014. 142 funds tracked by Wall St. Rank hold AGIO as of Q4 2014.

  • Zweig-DiMenna Associates reported no remaining Agios Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 46,483 Agios Pharmaceuticals shares in Q4 2014, an estimated $2.85M.
  • Zweig-DiMenna Associates first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Agios Pharmaceuticals position peaked at $2.85M in Q3 2014.
  • 142 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2014, filed 12 Feb 2015.